Bepirovirsen Liver Biopsy Study

Overview

Bepirovirsen Liver Biopsy study is a single centre open label phase II study to examine the antiviral and immunological effects of bepirovirsen in CHB patients both treated and untreated with HBsAg\<1000 IU/ml

Detailed description

HYPOTHESIS AND OBJECTIVES Bepirovirsen, an ASO, has shown 19% Functional Cure rates in a phase 3 clinical trial but its intrahepatic mechanism of action is unclear, possibly through immune mechanisms since animal studies show a significant proportion of Bepirovirsen accumulates in non-parenchymal cells of the liver. Investigating the immunological and virological intrahepatic microenvironment before and during Bepirovirsen therapy will lead to insights into the mechanism of HBsAg loss, and differentiate sustained responders from transient responders.

Study Aims

1. Determine the functional cure rate in Chronic Hepatitis B (CHB) patients with qHBsAg ≤1000 IU/ml treated with Bepirovirsen weekly for 24 weeks at the end of the study at 72 weeks and 60 weeks for patients on NA therapy and not on NA therapy respectively 2. Determine the immunological and virological effects of Bepirovirsen in the intrahepatic microenvironment using paired liver biopsies

Primary Objective 1. Proportion of patients with functional cure in CHB patients who have qHBsAg ≤1000 IU/ml treated with Bepirovirsen

Secondary Objectives

1\. Determine intrahepatic immune cell types and pathways activated by Bepirovirsen

Interventions

• Drug Bepirovirsen
  Weekly Bepirovirsen treatment for 24 weeks, with loading doses
• Procedure Liver biopsy
  Liver biopsy as previously described
• Procedure Optional Liver biopsy
  An optional Liver biopsy as previously described

Primary outcome measures

• Functional cure rate after 24 weeks of weekly Bepirovirsen therapy at the end of the study at 72 weeks and 60 weeks for participants on NA therapy and not on NA therapy respectively. [Time frame: 72 weeks]

Secondary outcome measures (4)

• Changes in intrahepatic virology [Time frame: Up to week 72]
• Changes in Intrahepatic immunology [Time frame: Up to week 72]
• Changes in blood biomarkers [Time frame: Up to week 72]
• Safety measurements including adverse events (AEs) and serious adverse events (SAEs) [Time frame: Up to week 72]

Eligibility criteria

Inclusion criteria

• At least 21 years of age at the time of signing the informed consent.
• Documented to be HBsAg positive for ≥ 6 months prior to Screening.
• Currently receiving stable NA therapy (defined as no changes to their NA regimen from at least 6 months prior to Screening and with no planned changes to the stable regimen over the duration of the study), or not receiving any Hepatitis B treatment for at least 6 months, or Hepatitis B treatment naïve.
• qHBsAg ≤1000 IU/ml
• Alanine aminotransferase (ALT) ≤2x ULN
• A female participant is eligible to participate if she is not pregnant or breastfeeding, and 1 of the following conditions applies:

• Is a woman of non-childbearing potential
• Is a woman of childbearing potential and using a contraceptive method
• Capable of giving signed informed consent

Exclusion criteria

• qHBsAg > 1000 IU/ml
• Do not consent to participate in the Bepirovirsen Liver Biopsy study
• Clinically significant abnormalities or clinically significant physical examination findings (e.g. major surgery within 3 months of screening)
• Past history of or current co-infection with Hepatitis C infection, Human immunodeficiency virus (HIV) or Hepatitis D virus
• History of or liver cirrhosis as determined by:

• Fibroscan > 12kPa
• Participant's historic record of either/both liver biopsy or liver stiffness measurements in their medical records where their results are Liver biopsy Metavir Score is F4, they will be excluded from the study(If the participant has inconsistent clinical picture of cirrhosis, confirm and discuss eligibility with an investigator)
• Diagnosed with hepatocellular carcinoma as evidenced by Alpha-fetoprotein concentration ≥200 ng/mL or if the screening alpha fetoprotein concentration is ≥50 ng/mL and <200 ng/mL, the absence of liver mass must be documented by imaging within 6 months of or at screening. Cases should be discussed with an investigator.
• History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
• History of vasculitis or presence of symptoms and signs of potential vasculitis, current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition
• History of extrahepatic disorders possibly related to HBV immune conditions
• Current/History of alcohol or drug abuse/dependence as judged by the investigator to potentially interfere with participant compliance
• Currently taking, or took within 3 months of screening, any immunosuppressing drugs, other than a short course of therapy (≤2 weeks) or topical/inhaled steroid use.
• Participants requiring anti-coagulation therapies or anti-platelet agents unless treatment can safely be discontinued throughout duration of Bepirovirsen treatment, by the discretion of the investigator. Occasional use is permitted.
• The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives (if known) or twice the duration (if known) of the biological effect of the study treatment (whichever is longer) or 90 days (if half-life or duration is unknown).
• Prior treatment with any oligonucleotide or siRNA within 12 months prior to the first dosing day
• Prior treatment with Bepirovirsen within 6 months
• Fridericia's QT correction formula (QTcF) ≥450 msec (if single ECG at screening shows QTcF ≤450 msec, a mean of triplicate measurements should be used to confirm that participant meets exclusion criterion).
• Laboratory results as follows:

• Serum albumin ≤3.5 g/dL
• Glomerular filtration rate (GFR) ≤60 mL/min/1.73m2 as calculated by the CKD-EPI formula
• INR >1.25
• Platelet count <140 x 109/L
• Total bilirubin >1.25x ULN (For participants with benign unconjugated hyperbilirubinemia with total bilirubin >1.25x ULN, discussion for inclusion to the study is required with the investigator)
• Urine albumin to creatinine ratio (uACR) >0.3 mg/mg (or >300 mg/g). (In the event of an uACR above this threshold, eligibility may be confirmed by a second measurement. In cases where results are shown as unable to perform (UTP), please check the individual labs and confirm that the participant has urine albumin and/or urine creatinine within normal levels. The investigator should confirm that the participant does not have a history of medical conditions or other risk factors that may affect renal function)
• History of/sensitivity to Bepirovirsen or components thereof or a history of drug or other allergy that, in the opinion of the investigator, contraindicates their participation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Singapore · 1 center

• Division of Gastroenterology & Hepatology, National University Hospital (NUH) — Singapore

Identifiers

NCT: NCT07696520 · 2025-1414

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗